Cost effectiveness analysis of population-based serology screening and 13C-Urea breath test for Helicobacter pylori to prevent gastric cancer: A markov model

Table 2 Incremental cost-effectiveness ratios of screening strategies at age 40 yr (compared to no screening strategy unless stated)

US$/QALY	Base-case		Best-case1		Worst-case1
	Serology	UBT	Serology	UBT	Serology	UBT
ICER per life year saved	16 166	38 792	Dominant	Dominant	389 728	640 000
		477 0792		Dominant2		5 645 4492
ICER per QALY gained	13 571	32 525	Dominant	Dominant	324 773	560 000
		390 3372		Dominant2		Dominated2

ICER: Incremental cost-effectiveness ratio; QALY: Quality-adjusted life year; UBT: ¹³C-Urea breath test.

¹Variables modified in best and worst-case analyses were, gastric cancer risk reduction by eradication (100% and 10%, respectively), relative risk (12 and 2), cost of annual gastric cancer treatment ($59 000 and $328), cost of the serology screening ($10 and $50), cost of the UBT ($60 and $100), and annual discount rate (0% and 7%);

²The ICER was calculated by comparing the UBT with the serology screening.